Abstract
Pre-eclampsia (PE) is a systemic maternal syndrome affecting 2-8% of pregnancies
worldwide and involving poor placental perfusion and impaired blood supply to the foetus.
It manifests after the 20th week of pregnancy as new-onset hypertension and substantial
proteinuria and is responsible for severe maternal and newborn morbidity and
mortality. Identifying biomarkers that predict PE onset prior to its establishment would critically
help treatment and attenuate outcome severity. MicroRNAs are ubiquitous gene
expression modulators found in blood and tissues. Trophoblast cell surface antigen
(Trop)-2 promotes cell growth and is involved in several cancers. We assessed the PE
predictive ability of maternal miR-125b in the first trimester of pregnancy by measuring
its plasma levels in women with normal pregnancies and with pregnancies complicated
by PE on the 12th week of gestation. To gain insight into PE pathogenesis we investigated
whether Trop-2 is targeted by miR-125b in placental tissue. Data analysis demonstrated
a significant association between plasma miR-125b levels and PE, which together with
maternal body mass index before pregnancy provided a predictivemodel with an area
under the curve of 0.85 (95% confidence interval, 0.70-1.00). We also found that Trop-2 is
a target ofmiR-125b in placental cells; its localization in the basal part of the syncytiotrophoblast
plasma membrane suggests a role for it in the early onset of PE. Altogether,
maternal miR-125b proved a promising early biomarker of PE, suggesting that it may be
involved in placental development through its action on Trop-2 well before the clinical
manifestations of PE.
Lingua originale | English |
---|---|
pagine (da-a) | 1-15 |
Numero di pagine | 15 |
Rivista | Translational Research |
DOI | |
Stato di pubblicazione | Pubblicato - 2020 |
Keywords
- microRNA-125b
- pre-eclampsia